Physician profile
Gene A Germano
NPI 1881870442
$3,272.08
in general payments reported to CMS, 2019-2025
17 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 82% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2021: $160 · 2022: $358 · 2023: $193 · 2024: $750 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.41 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,208.13 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $527.73 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $278.31 | 2021-2025 | Caplyta |
| Alkermes, INC. | $201.38 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Braeburn INC. | $179.20 | 2023-2025 | Brixadi |
| Indivior INC. | $166.14 | 2021-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $116.10 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $89.75 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $81.33 | 2025 | Cobenfy |
| Gilead Sciences, INC. | $73.79 | 2024-2025 | |
| Uswm, LLC | $43.72 | 2024 | Lucemyra |
| Axsome Therapeutics, INC. | $26.01 | 2023 | Auvelity |
| Tms Neurohealth Centers INC. | $23.23 | 2025 | Tms Neurohealth Centers INC. |
| Teva Pharmaceuticals USA, INC. | $20.89 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.27 | 2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $16.10 | 2024 | Abilify Maintena, Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Germano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.